EG 427
Entity

  • EG 427

    Created in 2019
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups

  • Social networks

    1,180

  • Activities

    biotech healthtech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    29 Rue du Faubourg Saint-Jacques, 75014 Paris, France

    Paris

    France

  • Employees

    Scale: 11-50

    Estimated: 20

  • Engaged corporates

    2
    2 0

  • Added in Motherbase

    8 months, 4 weeks ago
Description
  • Value proposition

    Pinpoint Gene Therapy - We are Hiring!

    At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond.
    Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, is expected to be in the clinic by early 2024. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care.

    Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 15 million, including from our Series A in 2021.

    Gene therapy, peripheral nervous system disorders, neurogenic bladder, HSV-1 vector platform, urinary bladder dysfunction, Herpes type 1 gene therapy platform, and treatment of nervous system disorders

  • Original language

    Pinpoint Gene Therapy - We are Hiring!

    At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond.
    Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, is expected to be in the clinic by early 2024. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care.

    Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 15 million, including from our Series A in 2021.

Corporate interactions BETA
Corporate TypeTweets Articles
Paris Biotech Santé
Paris Biotech Santé
Startup accelerator & VC, Civic and Social Organizations
Paris Biotech Santé
Startup accelerator & VC, Civic and Social Organizations 		Other

20 Oct 2023


SATT Paris-Saclay
SATT Paris-Saclay
Research, Startup accelerator & VC, Research Services
SATT Paris-Saclay
Research, Startup accelerator & VC, Research Services 		Other

25 Sep 2023


Similar entities
Last news
Show all articles
Social network dynamics